Related Experiment Video

Updated: Aug 22, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Integrative Transcriptomic Analysis Identify Potential m6A Pathway-Related Drugs That Inhibit Cancer Cell

Jingkun Yi1, Rucong Liu1,2, Yu Liu1

  • 1Department of Biomedical Informatics, MOE Key Lab of Cardiovascular Sciences, School of Basic Medical Sciences, Peking University, Beijing 100191, China.

Genes
|November 11, 2022
PubMed

Insights

New drugs AZ628 and R428 show promise in inhibiting cancer cell proliferation by targeting N6-methyladenosine (m6A) modification. These findings offer potential new therapeutic strategies for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • N6-methyladenosine (m6A) mRNA modification is increasingly recognized for its role in cancer progression.
  • Comprehensive understanding of drugs targeting m6A methylation to inhibit cancer cell proliferation remains limited.

Purpose of the Study:

  • To identify novel m6A-related drug candidates for cancer therapy.
  • To investigate the efficacy of identified drugs in inhibiting cancer cell proliferation.

Main Methods:

  • Integrative analysis of transcriptome data with m6A writer/eraser perturbation.
  • Identification of consensus m6A-related differentially expressed genes (DEGs).
  • Comparative analysis with Connectivity Map signatures to predict potential m6A-targeted drugs.

Main Results:

  • Identified consensus m6A-related DEGs and highlighted potential m6A-targeted drugs.
  • Experimentally verified AZ628's inhibition of human breast cancer cell proliferation.
  • Experimentally verified R428's inhibition of human melanoma cell proliferation.
  • Both drugs significantly reduced cellular m6A modification levels.

Conclusions:

  • AZ628 and R428 represent potential new therapeutic agents targeting m6A modification pathways.
  • These drugs demonstrate efficacy in inhibiting proliferation of breast cancer and melanoma cell lines.
  • Further research into m6A-targeted therapies is warranted.
Keywords:
cancer cell proliferationconnectivity mapdrugm6A methylationtranscriptome

More Related Videos

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

851
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K